XTNT

Xtant Medical Holdings, Inc.

$0.27

-1.47%
SectorHealthcareIndustryMedical DevicesCountryUnited States

Xtant Medical Holdings, Inc. provides regenerative medicine products and medical devices for orthopedic and neurological surgeons in the United States and internationally. It offers OsteoSponge, a natural scaffold for cellular in-growth; OsteoSelect DBM Putty, a moldable demineralized bone matrix; OsteoSelect PLUS DBM Putty to deliver handling properties and ensure patient safety through validated and terminal sterilization; 3Demin, a family of allografts that maximizes osteoconductivity and the osteoinductive potential of human bone; OsteoFactor Pro, a processed allograft that contains retained growth factors found within the endosteum layer of allograft bone; OsteoVive Plus, an aseptically processed and viable bone allograft; and nanOss products that provide osteoconductive nano-structured hydroxyapatite and an engineered extracellular matrix bioscaffold collagen carrier.

Source: Yahoo Finance
AI summary

Price & performance

1M-3.0%
3M-30.4%
YTD-57.3%
1Y-58.4%
52-week range—
Beta0.77
Full chart and returns against a benchmark

Q-Score

47/ 100

Quality against peers; 50 is the peer median.

Growth42
Risk51
Performance34
Valuation66
Profitability61
Leverage43
Sentiment39
Every score and metric

News sentiment

Open News

Latest results · FY 2025

Revenue$133.9M+14.2%
Net income$5M
Net margin3.7%+17.7 pts
Historical fundamentals

Red flags in filings

2active red flags
Material weakness in controlsMar 31, 2026
Debt default or accelerationDec 3, 2025
Filings, findings and the timeline

Revenue exposure

9%of revenue from outside the US
United States91%
Non Us9%
Regions, segments, customers and suppliers

Valuation

XTNTIndustryP/E—29.61P/S0.353.49EV/EBITDA—18.38P/B0.963.39PEG——
Dividend yield0.00%
Every valuation metric

Earnings

Nov 16next report, before the open
EPS estimate$-0.02
Beats (last 4 quarters)—
Average surprise—
EPS revisions (30d)—
Every quarter against its estimate